Maximum Tolerated Dose of a Humanized Anti-Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration

The maximum tolerated single dose of ranibizumab in neovascular AMD patients was 500 μg. Single intravitreal injections of ranibizumab up to a dose of 500 μg were safe and well tolerated in this small group of patients.